Despite rapid advancements
in antitumor drug delivery, insufficient
intracellular transport and subcellular drug accumulation are still
issues to be addressed. Cancer cell membrane (CCM)-camouflaged nanoparticles
(NPs) have shown promising potential in tumor therapy due to their
immune escape and homotypic binding capacities. However, their efficacy
is still limited due to inefficient tumor penetration and compromised
intracellular transportation. Herein, a yolk–shell NP with
a mesoporous silica nanoparticle (MSN)-supported PEGylated liposome
yolk and CCM coating, CCM@LM, was developed for chemotherapy and exhibited
a homologous tumor-targeting effect. The yolk–shell structure
endowed CCM@LM with moderate rigidity, which might contribute to the
frequent transformation into an ellipsoidal shape during infiltration,
leading to facilitated penetration throughout multicellular spheroids in vitro (up to a 23.3-fold increase compared to the penetration
of membrane vesicles). CCM@LM also exhibited a cellular invasion profile
mimicking an enveloped virus invasion profile. CCM@LM was directly
internalized by membrane fusion, and the PEGylated yolk (LM) was subsequently
released into the cytosol, indicating the execution of an internalization
pathway similar to that of an enveloped virus. The incoming PEGylated
LM further underwent efficient trafficking throughout the cytoskeletal
filament network, leading to enhanced perinuclear aggregation. Ultimately,
CCM@LM, which co-encapsulated low-dose doxorubicin and the poly(ADP-ribose)
polymerase inhibitor, mefuparib hydrochloride, exhibited a significantly
stronger antitumor effect than the first-line chemotherapeutic drug
Doxil. Our findings highlight that NPs that can undergo facilitated
tumor penetration and robust intracellular trafficking have a promising
future in cancer chemotherapy.